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Nucleic acid amplificationmethods such as the PCR have had a major impact on the diagnosis of viral infections, often achieving
greater sensitivities and shorter turnaround times than conventional assays and an ability to detect viruses refractory to conven-
tional isolation methods. Their effectiveness is, however, significantly influenced by assay target sequence variability due to nat-
ural diversity and rapid sequence changes in viruses that prevent effective binding of primers and probes. This was investigated
for a diverse range of enteroviruses (EVs; species A to D), human rhinoviruses (HRVs; species A to C), and human parechovirus
(HPeV) in a multicenter assay evaluation using a series of full-length prequantified RNA transcripts. RNA concentrations were
quantified by absorption (NanoDrop) and fluorescence methods (RiboGreen) prior to dilution in buffer supplemented with
RNase inhibitors and carrier RNA. RNA transcripts were extremely stable, showing minimal degradation after prolonged storage
at temperatures between ambient and20°C and after multiple freeze-thaw cycles. Transcript dilutions distributed to six refer-
ral laboratories were screened by real-time reverse transcriptase PCR assays using different primers and probes. All of the labo-
ratories reported high assay sensitivities for EV and HPeV transcripts approaching single copies and similar amplification kinet-
ics for all four EV species. HRV detection sensitivities were more variable, often with substantially impaired detection of HRV
species C. This could be accounted for in part by the placement of primers and probes to genetically variable target regions.
Transcripts developed in this study provide reagents for the ongoing development of effective diagnostics that accommodate
increasing knowledge of genetic heterogeneity of diagnostic targets.
Infections with picornaviruses, human rhinoviruses (HRVs), en-teroviruses (EVs), and human parechoviruses (HPeVs) are fre-
quent in human populations worldwide. Diseases associated with
these viruses range from the common cold and exacerbation of
asthma and bronchitis to severe infections of the central nervous
system (CNS) and myocardium. EVs and HRVs are classified as
members of the Enterovirus genus (27, 46), a diverse group of
human, monkey, and other mammalian viruses, while HPeV is a
member of the Parechovirus genus, along with the rodent Ljungan
virus (13, 19, 49). The 93 human EVs fall into four genetically
distinct species, human EV species A (EV-A) to EV-D (20, 46).
Species B variants (echoviruses, Coxsackie B viruses, and Cox-
sackie A virus 9 [CAV-9]) are themostly frequently identified viral
causes of CNS-associated infections in Western countries and,
along with species A serotype EV71, in Southeast Asia. Human
rhinoviruses fall into three species, HRV-A to -C, containing 75,
25, and60 types, respectively (45, 46). The disease associations
of different HRV species and types are similar, although with in-
creasing evidence of greater disease severity reported for species C
(reviewed in reference 29). The common HPeV variants found in
Europe are types 1, 3, 4, and 6, with a recently described associa-
tion between type 3 infections and severe neonatal infections lead-
ing to sepsis (5, 6, 14).
Screening, surveillance, and investigation of the disease associ-
ations of different EV, HRV, and HPeV types require assays that
are effective for the range of genetic variants found in diagnostic
samples. Assays that target the highly conserved 5= untranslated
regions (UTRs) of these viruses (typically by real-time PCR) (2, 9,
18, 37, 51) therefore need to accommodate naturally occurring
sequence variability in this region to ensure equal sensitivity. Sim-
ilarly, virus species and type identification through amplification
and sequencing of coding regions such as VP1 in the case of EVs
and HPeV (14, 35, 36) and VP4 for HRVs (31, 42) require often
quite degenerate primer sequences to allow effective amplification
of these more divergent regions of the genome.
In the current study, we have addressed one of themajor prob-
lems with evaluating the performance of screening and virus typ-
ing assays for EVs and PeVs through the creation of a set of stan-
dardized RNA transcript controls. Each is quantified in absolute
numbers of RNA copies, and together they represent the wide
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range of naturally occurring EV, HRV, and HPeV variability.
While RNA transcripts have been widely used as individual con-
trols for the diagnostic screening of several human viruses, includ-
ing noroviruses, flaviviruses, EVs, and rhinoviruses (11, 28, 44, 47,
48), this study extends their use to create larger panels represent-
ing the full genetic diversity of EV-A to -D, rhinoviruses A and B,
recombinant (Ca) and nonrecombinant (Cc) variants of HRV-C
(17), and HPeV type 1 (HPeV-1). Comparative evaluation of the
sensitivity and amplification dynamics of awide range of currently
implemented real-time PCRs for these viruses, along with several
different typing methods, provides considerable insights into the
performance of these assays and how they may be potentially im-
proved. For example, their use has revealed frequent potential
sensitivity problems with HRV-C detection.
MATERIALS AND METHODS
Human EV, rhinovirus, and HPeV-1 transcripts. Full-length cDNA
clones of CAV-16 (accession number U05876), echovirus 7 (E7) and E30
(AF465516 and GB-27 [unpublished]), CAV-21 (D00538), and EV70
(D00820) representing EV-A to -D (A,CAV-16; B, E7, E30; C, CAV-21;D,
EV70) were kindly provided by D. J. Evans, University of Warwick. Rhi-
novirus species A (HRV-A1b; D00239) and B (HRV-B14; X01087) and
the HPeV-1 clone (Harris isolate; FM242866) were provided by G. Stan-
way, University of Essex. For recombinant HRV-C (HRV-Ca) and non-
recombinant (HRV-Cc) variants, 5= UTR-VP4-partial VP2 clones were
assembled from amplified sequences from the variants R4636/07 (HRV-
Cpat19; Cc) and R3092/06 (HRV-C40; Ca) (45).
Plasmids were linearized at the 3= end and purified by phenol-chloro-
form extraction and ethanol precipitation. Sense orientation RNA tran-
scriptswere generated byT7RNApolymerase using aMEGAscript in vitro
RNA transcription kit (Ambion UK) according to the manufacturer’s
protocol. Transcribed RNAwas DNase treated prior to precipitation with
lithium chloride. Newly transcribed RNA was analyzed for integrity on a
denaturing RNA-agarose gel with 2.2 M formaldehyde.
RNA quantification. RNA transcript concentrations were quantified
by using twomethods, a NanoDrop ND-1000 quantifying optical density
at 260 nm and the Quant-iT RiboGreen RNA quantification system, ac-
cording to manufacturer’s protocol (Invitrogen UK). The RNA concen-
trations determined by the two assays correlated closely (data not shown).
RNA concentrations were converted to numbers of genome copies by
assuming a mean molecular mass of each base of 330 g/mol. RNA was
diluted in RNA storage solution (1 mM sodium citrate, 0.1 mM EDTA,
pH 6.0; Ambion UK) containing 0.05 g/ml herring sperm carrier RNA
and 0.1 U/ml RNasin (New England BioLabs UK). Dilutions of RNAwere
aliquoted and stored at20°C prior to testing distribution and distribu-
tion to referral laboratories. For long-term storage, RNA in storage solu-
tion was archived in aliquots at80°C.
Transcript amplification by real-time PCR. Dilution series of tran-
scripts (105 to 102 copies/l) were amplified singly or in replicate using
routine real-time reverse transcriptase PCR (RT-PCR) assays designed for
diagnostic testing for EV,HRV, andHPeVby five laboratories performing
real-time PCR detection of EVs, HPeV, andHRV. These were the Special-
ist Virology Laboratory, Edinburgh Royal Infirmary, Edinburgh, United
Kingdom (3); the Regional Virology Laboratory, Gartnavel Hospital,
Glasgow, United Kingdom; the Regional Virology Laboratory, Royal Vic-
toria Hospital, Belfast, United Kingdom; the Health Protection Agency
(HPA) laboratory, Bristol, United Kingdom; the Department of. Medical
Microbiology, Academic Medical Centre, Amsterdam, The Netherlands
(EV and HPeV only); and the Department of Virology, University of
Turku, Turku, Finland (EV and HRV only). Assays used different prim-
ers, probes, and amplification conditions.
Specialist Virology Laboratory, Edinburgh, United Kingdom. Real-
time PCR assays for EVs and HPeVs were performed as previously de-
scribed (13). HRV screening was performed under the same reaction con-
ditions and with the primers and probes previously described (43).
Regional Virology Laboratory, Gartnavel Hospital, Glasgow, United
Kingdom. Real-time PCR assays for EVs and HPeVs were performed as
previously described (3). HRV screening was done with the primers and
probes previously described (7).
RegionalVirologyLaboratory,Belfast,UnitedKingdom.Single-step
TaqMan RT-PCR assays targeting the 5= UTR were used to detect EV and
HRV. Assays used the Superscript III Platinum One-Step Quantitative
RT-PCR System (Invitrogen, Carlsbad, CA) in 10-l reaction mixture
volumes comprising 0.2 l Superscript III RT Taqmix, 5 l2 Reaction
Mix (containing 0.4 mM each deoxynucleoside triphosphate [dNTP]),
3.5 mM MgSO4, 0.4 M each primer, 0.2 M probe, and nuclease-free
water to a volume of 8 l. Two microliters of transcript was added as the
template, giving a final reaction volume of 10 l. Real-time RT-PCR was
performed in 96 white-well plates using the Roche 480 LightCycler II
(Roche, Mannheim, Germany). Cycling conditions were as follows: 50°C
for 15 min, 95°C for 5 min, and 45 cycles of 95°C for 10 s and 60°C for 60
s. The primer and probe sequences used for EV and HRV detection were
as follows: EV 1A, TCC TCC GGC CCC TGA ATG; EV 1B, GAA ACA
CGG ACA CCC AAA GTA; EV 1P, 6-carboxyfluorescein (FAM)-CGGT
TCCGCYRCAGA-MGBNFQ;HRV 1A, AGCCTGCGTGGCTGCCTG;
HRV 1A2, CCTGCGTGGCGGCCARC; HRV 1B, CCCAAAGTAGTY
GGT CCC RTC C; HRV 1P, FAM-TCC TCC GGC YCC TGA ATG-MG
BNFQ.
Department of Medical Microbiology, Amsterdam, The Nether-
lands. RNA was directly transcribed by rHex cDNA reaction (40 l) (5),
and 5l of transcribed cDNAwas amplified by real-time PCR for EV and
HPeV as previously described (4).
Department ofVirology,University of Turku, Turku, Finland.HRV
andEV transcriptswere detected inRT-PCRassayswith universal primers
from the 5= UTR (38). RNA transcripts were reverse transcribed with
Moloney murine leukemia virus (MMLV) RNase H transcriptase (Pro-
mega) in a reaction mixture containing 40 U of the RT enzyme, 4 U of
RNasin RNase inhibitor, 500 nM dNTP, 1.2 M ENRI4 primer (GAA
ACACGGACACCCAAAGTA), RT buffer, and 5l of RNA transcript in a
total volume of 20 l. cDNA synthesis was carried out at 42°C for 1 h.
Amplifications with SYBR green detection were performed in 25-l reac-
tion mixtures with Maxima SYBR master mix (Fermentas), 600 nM
ENRI3 (CGGCCCCTGAATGCGGCTAA) and ENRI4 primers, and 5
l of cDNA using a Rotor Gene 6000 instrument (Corbett Research). The
amplification program included the following steps: 15 min at 95°C; 45
cycles of 15 s at 94°C, 30 s at 65 to 56°C (touchdown, 1°C/cycle for the first
10 cycles), and 40 s at 72°C; and melting at 72 to 95°C at increments of
1°C/5 s. Amplifications with proprietary FAM (HRV)- or Cy5 (EV)-la-
beled probeswere performed analogously withMaximaProbemastermix
(Fermentas) without melting curve generation.
HPA, Bristol, UnitedKingdom.Reverse transcriptionwas performed
in 25-l volumes using 100 U MMLV RT (Promega) and 0.5 mg/ml
random hexamers for 30 min at 37°C, followed by 10 min at 95°C. Real-
time PCRwas performed in 20-l reaction volumes consisting of ABI Fast
Universal Master Mix (Applied Biosystems) with 5 l cDNA and primers
and probes as described below. A two-temperature thermal cycling pro-
tocol (95°C denaturation and 60°C annealing/extension) was used. The
primers and probe used for rhinovirus detection were as follows: HuRV-
MG1F forward primer, GACARGGTGTGAAGAGCC (300 nM); HuRV-
MG1R reverse primer, CAAAGTAGTYGGTCCCATCC (300 nM);
HuRV-MG2F forward primer, GACATGGTGTGAAGACYC (300 nM);
HuRV-MGPTaqManprobe, (JOE/BHQ)TCCTCCGGCCCCTGAATGY
GGCTAA (100 nM). The primers and probe used for EV detection were
as follows: EV-F forward primer, CCCCTGAATGCGGCTAATC (300
nM); EV-R reverse primer, ATTGTCACCATAAGCAGCCA (300 nM);
EV68aR reverse primer, GTCACCATTAGCAGTCATAAAAGTAA (300
nM); EV-P TaqMan probe, (FAM/BHQ) CGGAACCGACTACTTTGGG
TGTCCGT (100 nM). The primers and probes used for PeV detection
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were as follows: PeV-CCF forward primer, CACTAGTTGTAAGGCCCA
CGAA (300 nM); PeV-CCR reverse primer, GGCCCCAGATCAGA
TCCA (300 nM); PeV-CCP TaqMan probe, (Cy5/BHQ) CAGTGTCTCT
TGTTACCTGCGGGTACCTTCT (100 nM) (10).
Results from different referral laboratories were normalized to take
into account differences in RNA (and, where relevant, cDNA) volumes in
different assays.
Other PCR assays. EV, HRV, and HPeV sequences were amplified by
a range of virus typing and reference tests used in the Specialist Virology
Laboratory, University of Edinburgh. EV and HRV transcripts were as-
sayed in six replicates by nested PCRs using the primer pairs from the 5=
UTR (50) and the VP4/partial VP2 region (50). VP1 regions were ampli-
fied for EV-A, -B, and -D as previously described (16, 26). Species C
sequences were amplified by newly designed primers from VP2 (outer
sense, position 1172 [5= base numbered in the poliovirus Leon type 3
isolate, accession number K01392], TCNMRRGGRTGGTGGTGGAA;
inner sense, position 1223, TTYGGNCARAAYATGTAY TAYCAYTA;
outer antisense, position 1731, CCR TTRAAY TCRCWRCACATNGG;
inner antisense, position 1629, CCC CAR TTR TTR TGY TTN RCC AT).
HPeV sequences were amplified in the 5= UTR (15) and the VP3-VP1
junction (14).
RNA stability. EV-B (E30) and -A (CAV-16) transcripts were investi-
gated for stability at different temperatures. A 100-l volume of a 104-
copy/l dilution of each was incubated in storage solution for up to 30
days at ambient temperature, 4°C, and 37°C; an aliquot of each was also
freeze-thawed three times. To determine the possible contribution of re-
sidual contaminating template DNA to RT-PCR results, control reaction
mixtures without a reverse transcription step were prepared in parallel; all
control reaction mixtures were negative at the highest transcript concen-
tration tested (60,000 RNA copies/reaction mixture).
Nucleotide sequence accession numbers. Composite sequences of
R4636/07 (HRVCpat19; Cc) and R3092/06 (HRV-C40; Ca) have been
deposited in GenBank and assigned accession numbers JX276744 and
JX276745, respectively.
RESULTS
Amplification of transcripts by real-time RT-PCR. Dilution se-
ries of the RNA transcripts ranging from 105 to 102 copies/l
were assayed by a previously described EV/HPeV multiplexed
PCR method (3) (Fig. 1). The five EV transcripts showed highly
reproducible amplification dynamics by real-time PCRwith a lin-
ear relationship between the log10-transformed RNA input copy
number (x axis) and the cycle threshold (CT) value. Amplification
efficiencywas close to 100% (data not shown). For each transcript,
the assay endpoint sensitivity lay between 0.9 and 9 RNA copies
(Fig. 2A), apart fromnegative results for one of two of the replicate
assays of E30 and EV70. Assay of the EV transcripts by other lab-
oratories yielded similarly consistent results (Fig. 3), although
there was marked variability in amplification rates between the
laboratories (CT value of a nominal 1,000 RNA copies), ranging
from around 32 (Edinburgh and Amsterdam) to 23 (Turku).
There was a similarly wide range of endpoint sensitivities (0.4 to
20 RNA copies) between the laboratories (Fig. 2A), although sen-
sitivity was generally consistent among the five EV transcripts
tested by each laboratory. Two-log reduced sensitivity for the spe-
cies C transcript was observed on testing by the Bristol and Turku
laboratories and additionally for speciesD by the latter laboratory.
Much more variable amplification dynamics were observed
with HRV transcripts, with assays from many laboratories show-
ing reduced sensitivity for species B and C transcripts. For exam-
ple, amplification of the HRV-A transcript in the multiplexed as-
say in Edinburgh showed amplification dynamics similar to those
of EV-A to -D, while amplification of HRV-B and -C was much
slower (Fig. 1B and 3A) and showed reduced assay sensitivity
(Fig. 2A). Comparison of testing for HRV transcripts from each
laboratory assay showed a consistent trend toward lower amplifi-
cation rates and endpoint sensitivities for HRV than for EV and
HPeV transcripts (Fig. 2A and 3), particularly for species C. In
marked contrast, all of the assays detected HPeV RNA sequences
with rates and sensitivities similar to those for EVs.
The observed variability of assay sensitivities and amplifica-
tion efficiencies could be accounted for, at least in part, by the
existence of sequence mismatches of primer and probe se-
FIG 1 Replicate testing of EV (A), HRV (B), and HPeV (C) transcripts using
the multiplexed PCR from the Specialist Virology Laboratory, Edinburgh
Royal Infirmary. The nonrecombinant and recombinant HRV-C sequences
correspond to HRV-Cpat19 (Cc) and HRV-C40 (Ca), respectively.
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quences and the target sequences (Fig. 4). The primers used for
EV detection were targeted in conserved regions between po-
sitions 416 and 606 within the 5= UTR. With the exception of
the sense primers used in Edinburgh and Glasgow (11), none of
the primers or probes mismatched transcript target sequences.
However, the one or two mismatches between the sense primer
and EV evidently had little effect on assay performance; similar
detection efficiencies were observed for transcripts from all
four species (Fig. 2A and 3).
Primers andprobes used forHRVdetectionwere, in general, sim-
ilarly conserved in the target regions among HRV variants (Fig. 4B).
As for EV, few, if any, mismatches were observed with any of the
real-time PCR methods, although many assays showed reduced
sensitivity for species C rhinoviruses. In the Edinburgh real-time
PCR, the poor sensitivity for species C might plausibly have arisen
through the two mismatches toward the 3= end of the antisense
primer. All of theHPeV primers and probes showed perfectmatches
to the HPeV1 transcript (data not shown).
Finally, although the transcripts used in the assay represent a
substantial proportion of the naturally occurring sequence diver-
sity of EVs, HRVs, and HPeV, additional variability is shown
among the full currently described data set of known types within
each species. To illustrate this, strict and 95%consensus sequences
were constructed from alignments of each of the described types
within EVs and HRVs (Fig. 4). Primers and probes showed many
potential mismatches with one or more described variants within
EVs and HRVs at numerous positions. For example, both sense
and antisense primers fir HRV used by Edinburgh and Glasgow
targeted regions in the 5=UTR that were quite variable, withmany
positions showing less than 95% conservation among the broader
set of HRV types (Fig. 4B). Better conservation was observed in
EVs (Fig. 4A) and HPeV-1 to -6 (data not shown).
FIG 2 Endpoint sensitivities for EV, HRV, and HPeV transcript sequences of 5= UTR-based real-time assays from referral laboratories (A) and 5= UTR and
coding region nested PCR assays (the latter used for typing) (B). For real-time PCR, mean values are shown where testing was carried out in replicate; for typing
assays, endpoints were calculated by 6-fold replicate testing in 10-fold dilution steps. Laboratory abbreviations: E, Specialist Virology Laboratory, Edinburgh
Royal Infirmary, Edinburgh, United Kingdom; G, Regional Virology Laboratory, Gartnavel Hospital, Glasgow, United Kingdom; Be, Regional Virology Labo-
ratory, Royal Victoria Hospital, Belfast, United Kingdom; Br, HPA, Bristol, United Kingdom; A, Department of. Medical Microbiology, Academic Medical
Centre, Amsterdam The Netherlands; T, Department of Virology, University of Turku, Turku, Finland.
FIG 3 Amplification rate (extrapolated or interpolatedCT values for 1,000 input
RNAcopies)withmeanvalues shownwhere testingwas carriedout in replicate for
eachreal-timeassay forEV,HRV,andHPeVtranscripts.Laboratoryabbreviations
are as in Fig. 2.
RNA Transcript Controls for Viral Diagnostic PCR
September 2012 Volume 50 Number 9 jcm.asm.org 2913
Sensitivity and specificity of primers used for EV and rhino-
virus typing. RNA transcripts were amplified by nested PCR as-
says for capsid-coding regions (VP4/partial VP2) of EVs and
HRVs, VP1 (EV-A, -B, and -D), partial VP2 (EV-C), and partial
VP3/VP1 (HPeV), which are used for (sero)type identification
(Fig. 2B; see Table S1 in the supplemental material). Dilutions
ranging from 105 to 102 copies/l were assayed in 6-fold repli-
cates. Frequencies of positives at each dilution were used to calcu-
late detected RNA concentrations that were compared with input
copy numbers to determine assay sensitivity. Amplification of EV,
HRV, and HPeV RNA transcripts by nested PCR in the 5= UTR
showed relatively high sensitivity and close concordance between
the input RNA copy numbers and the RNA copy numbers de-
tected (Fig. 2B). The sensitivities of the amplification methods for
the coding regions VP4/VP2 (EVs and HRVs), VP1 (EV-A, -B, and
-D), VP2 (EV-C), andVP3/VP1 (HPeV) ranged from equal sensitiv-
ity to an approximately 100-fold reduction. While these values may
vary between serotypes within a species (and could not be assessed
with the currentpanel of transcripts), thesefindingsprovide evidence
that typing assay sensitivity is broadly comparable between types.
RNA stability. Dilution of transcript RNA in a low-pH, RNase-
free solution containing carrier RNA was designed to enhance their
FIG 4 Primer matches to EV and HRV transcript sequences. Mismatches are highlighted with shaded boxes. Sequence alignments are numbered on the basis of
the CAV-16 sequence (accession no. U05876).
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longer-term stability and thus the reproducibility of assay evaluation
in referral laboratories. To investigate how stable the RNA prepara-
tions actually were, two representative EV transcripts (E30, CAV-21)
were subjected to a range of temperatures and freeze-thaw cycles and
their RNA content was assessed by real-time PCR (Fig. 5). No or
minimal changes in CT values (reflecting residual RNA concentra-
tions) were observed on freezing-thawing or incubation for up to 30
days at 4°C, while increases of approximately 2- and 8-fold were ob-
servedon incubationat roomtemperature and37°C for 30days (cor-
responding to approximately 4-fold and 250-fold reductions of am-
plifiable RNA sequences).
DISCUSSION
RNA transcripts of EV-A to -D, HPeV-1, and rhinoviruses A, B,
Ca, and Cc were developed for use as molecularly calibrated RNA
standards for validation and comparison of the assay sensitivities
of a range of real-time PCRs and typing protocols. This Clinical
Virology Network-initiated study is a response to the growing
need for independent external validation of molecular-analysis-
based diagnostic assays that have become the standard method of
virus detection (33, 40). For all three target groups of viruses,
substantial sequence diversity in most parts of the genome com-
plicates the development of effective assays capable of detection
and identification of all species and types. For each, the 5= UTR is
the most conserved region and is almost invariably targeted by
existing real-time PCRs for diagnostic screening. In the case of
EVs andHPeVs, screening of cerebrospinal fluid (CSF) in cases of
suspected viral meningitis and neonatal sepsis requires high assay
sensitivity and specificity due to the low viral loads in this com-
partment (8, 21, 32, 34). Recent developments of highly sensitive
multiplexed PCR assays therefore represent a significant advan-
tage in the screening of patients with these clinical presentations.
Indeed, the similarity of the sensitivities of each of the real-time
assays evaluated for different EV species provides reassurance that
the rarity of species C and D detection in CSF samples cannot be
directly attributed to assay insensitivity.
Rhinovirus screening presents a different set of difficulties. De-
spite its genetic diversity, PCR primers and probes for the 5= UTR
can also accommodate most of the sequence variability between
species. However, these target the same conserved regions found
in EVs and lead to substantial cross-amplification of EVs by HRV
primers and vice versa (12). As demonstrated by the highly vari-
able results from real-time screening of transcript dilutions, there
were also substantial differences in assay sensitivity for different
HRV species, most markedly for recombinant and nonrecombi-
nant species C variants that were frequently undetected or showed
2-log reductions in sensitivity compared to species A and B (Fig.
2). These findings are consistent with previous studies document-
ing the difficulty in species C detection by PCR.Combinedwith its
inability to be grown in cell culture, this may account for its rela-
tively late discovery in 2006 to 2007 (1, 22–25, 30, 39). The dem-
onstration of largely ineffective detection of species C will lead to
improved assay design and modified primer/probe sequences.
These can be reevaluated with the transcripts as part of its valida-
tion process; this process is under way in Edinburgh.
The same transcripts were used to evaluate the sensitivity of
EV, HRV, andHPeV typing assays based on the amplification and
sequencing of coding region sequences. This is necessary not only
because sequence variability in the 5= UTR is so restricted as to
preclude (sero)type identification, but the occurrence of recom-
bination between the 5= UTR and the rest of the genome (41) and
the consequent absence of species-specific 5= UTR sequences pre-
vent reliable species identification. A variety of typing assays have
been developed, in the case of EV and PeVs, in the VP1 region (5,
14, 35, 36), where sequences have been shown to be highly predic-
tive of EV and HPeV types. Similarly, VP4 sequences provide a
reliable indication of HRV types, a more conserved region of the
capsid gene that can be amplified with a common set of primers
(31, 42, 50).
Variable amplification efficiencies with nested primers from
the different capsid-encoding regions were observed (Fig. 2B),
observations that derive from primer mismatches with target se-
quences in the transcripts that cannot be fully accommodated
through the use of degenerate bases. However, sensitivity differ-
ences from screening (5= UTR-based) assays and from calculated
input RNA copy numbers were rarely greater than 100-fold (and
usually much lower). In the specific cases of EV-B and HPeV,
almost equivalent sensitivities compared to screening PCRs
may underlie the previously described high frequency of suc-
cessfully typed CSF samples despite their generally low viral
loads (13, 14, 26).
The use of an RNA dilution buffer specifically designed to pre-
vent RNA degradation through the incorporation of RNase
inhibitors and a low concentration of carrier RNA proved highly
effective atmaintaining high stability despite a variety ofmistreat-
ments (Fig. 5). The minimal effect of freezing-thawing and its
stability at both 4°C and ambient temperature suggest that dilu-
tion series of the RNA transcript standards can be relatively easily
distributedwithout the need for frozen shipment. Combinedwith
their lack of infectivity and extremely low cost of production and
distribution, these transcripts can be readily supplied to diagnos-
tic laboratories as a contribution to their quality assurance mech-
anisms and ongoing assay evaluations.
In summary, this study has successfully developed and evalu-
ated a series of RNA transcripts that capture much of the diversity
of EV and HRV and provide the means for laboratories to readily
evaluate their screening and typing assays in absolute (RNA copy
number) terms. These reagents could contribute substantially to
FIG 5 Stability of E30 and CAV-21 RNA transcripts determined by real-time
PCR assay (CT values, y axis) after incubation at different temperatures and for
different durations (24 h and 30 days [dy]) or freezing and thawing three times
(x axis).
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comparisons of assay sensitivities between laboratories, trouble-
shooting, and ongoing assay development as our understanding of
picornavirus diversity increases.
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